Compare PayPal Holdings, Inc. (PYPL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PayPal Holdings, Inc. trades at $55.52 (market cap $49.27B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: PayPal Holdings, Inc. is far larger — about 30.2× Recursion Pharmaceuticals Inc's market cap, and PayPal Holdings, Inc. pays a 1% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PYPL | RXRX | |
|---|---|---|
Market Cap | $49.27B | $1.63B |
Sector | Financials | Health |
52-Week High | $78.22 | $6.79 |
52-Week Low | $39.08 | $2.84 |
Enterprise Value | $49.33B | $1.05B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $55.85, down 1.26% today, amid takeover speculation from Stripe and Advent International. The stock shows strong fundamentals with a P/E of 10.66 and net income margin of 15%, while technical indicators are mixed with a bullish moving average signal but overbought RSI levels. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $6.42 billion in 2025.
The outlook is clouded by the potential buyout, which could limit upside if the offer is rejected, while profitability pressures and competition from Apple Pay pose risks. Analyst consensus is cautious with a hold-heavy rating, suggesting investors await clarity on strategic direction amid the takeover bid.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
